Plasma brain natriuretic peptide reflects left ventricular function during percutaneous cardiopulmonary support.

BACKGROUND: Plasma levels of brain natriuretic peptide (BNP), a cardiac hormone secreted predominantly from the ventricle, are elevated in patients with myocardial infarction, hypertension, and dilated cardiomyopathy. In this study, we assessed the usefulness of measuring BNP to evaluate left ventricular function in patients with severe heart failure receiving mechanical circulatory support. METHODS: Plasma BNP and creatine kinase (CK)-MB levels were measured serially in 8 consecutive patients with cardiogenic shock who received percutaneous cardiopulmonary support (PCPS) at Osaka Police Hospital from August 1999 to March 2000. Coronary artery bypass grafting or percutaneous transluminal coronary angioplasty was also performed in 5 patients during PCPS; in addition, 1 patient underwent insertion of a left ventricular venting catheter and implantation of a left ventricular assist system after PCPS. RESULTS: Five patients were weaned from PCPS, and 3 died. In survivors, plasma BNP and CK-MB levels correlated positively and significantly (r = 0.968, p = 0.03). After PCPS was initiated, plasma BNP levels gradually decreased in survivors, but not in patients who died (p = 0.003). CONCLUSIONS: These results suggest that plasma BNP levels accurately reflect myocardial damage in patients undergoing PCPS. A decrease in BNP might appear to indicate improved left ventricular function and predict successful weaning from mechanical support.

Mobilization of the posterior leaflet of the mitral valve for resection of a left ventricular tumor producing carbohydrate antigen 19-9.

We report an extremely rare case of a left ventricular tumor producing carbohydrate antigen 19-9 (CA19-9). A 43-year-old man with an episode of right hemiplegia underwent an emergent operation for a left ventricular tumor just beneath the posterior leaflet of the mitral valve. The tumor was successfully resected by mobilization of the posterior leaflet of the mitral valve. The resected specimen was immunoreactive for CA19-9.

Total arch replacement for thoracic aortic aneurysm via median sternotomy with or without left anterolateral thoracotomy.

BACKGROUND: Thoracic aneurysms involving the ascending aorta, arch, and descending aorta are usually approached in a series of operations. Here, we report our clinical experience with total arch replacement through a median sternotomy with or without left anterolateral thoracotomy, using a technique that preserves the anterior wall of the distal arch to avoid injuring the left recurrent and phrenic nerves. METHODS: Between March 1999 and February 2001, 32 consecutive patients underwent total arch replacement through a median sternotomy alone (median group, n = 23) or in combination with a left anterolateral thoracotomy (LAT group, n = 9). In all cases, antegrade hypothermic selective cerebral perfusion was used in conjunction with mild hypothermic visceral perfusion (cool head-warm body perfusion). RESULTS: There were no in-hospital deaths and two late deaths. One patient in the median group had permanent neurological dysfunction postoperatively. There were no significant differences between the two groups in bypass time, cardiac ischemic time, respiratory assist time, beginning peroral intake, hospital stay, or postoperative respiratory function. The distal anastomosis level was significantly lower in the LAT group (thoracic vertebra level 7.1 +/- 1.5 vs 5.6 +/- 0.5, p = 0.0015). CONCLUSIONS: Preservation of the anterior wall in the distal arch may decrease in-hospital mortality and perioperative neurological dysfunction after total arch replacement. Total arch replacement through a median sternotomy with left anterolateral thoracotomy allowed expeditious and extended replacement of the aorta without increasing postoperative respiratory complications.

Optimal arterial cannulation technique for selective cerebral perfusion in thoracic aortic surgery.

Despite advances in surgical procedures, anesthetic management, and cardiopulmonary bypass, brain injury remains a major source of morbidity and mortality in patients undergoing operations on the thoracic aorta. Here, we report our experience with arch vessel cannulation for selective cerebral perfusion in 32 consecutive patients with thoracic aneurysms who underwent total arch replacement between 1998 and 2000. The innominate vein was divided, and intraoperative epiaortic echography was performed to identify the least atherosclerotic site on brachiocephalic and left carotid arteries before establishment of cardiopulmonary bypass. There were no in-hospital deaths, and only 1 patient (3.1%) had a perioperative stroke. Identifying the least atherosclerotic site in cephalic branches is important for safely establishing selective cerebral perfusion and for preventing perioperative cerebral embolism during total arch replacement.

Swan-Ganz catheter-induced pseudoaneurysm of the pulmonary artery.

Pseudoaneurysm of the pulmonary artery (PA) induced by Swan-Ganz catheter injury is an important complication with high mortality. We report a case of PA pseudoaneurysm treated by PA repair. A 52-year-old woman developing infiltrate in the right lung field in chest radiography after a second mitral valve replacement was diagnosed with PA pseudoaneurysm confirmed by contrast-enhanced computed tomography and pulmonary angiography. The cause was considered Swan-Ganz catheter injury. The patient was carefully observed because there was no evidence of bronchial hemorrhage. The perforation was closed and the cavity plicated under extracorporeal circulation to avoid delayed rupture of the pseudoaneurysm when she underwent a third mitral valve replacement.

Acute thrombotic obstruction of mitral valve prosthesis: low protein C level.

A 51-year-old female underwent redo mitral valve replacement with a pericardial bioprosthesis because of acute thrombotic obstruction of a mechanical valve, in spite of adequate anticoagulation with warfarin. Her protein C level was 24% of the normal value and protein S was reduced to 54% of normal.

Postoperative changes in angiographically normal saphenous vein coronary bypass grafts using intravascular ultrasound.

We examined the process of vessel wall thickening in angiographically normal saphenous vein grafts (SVGs) using intravascular ultrasound. Fifteen SVGs were studied in the early stage (within 1 month postoperatively) and 14 SVGs in the late stage (over 6 months postoperatively). Lumen cross-sectional area (CSA) and vessel CSA were measured. Vessel wall area (VWA) was calculated and %VWA was defined as VWA / vessel CSA. Vessel CSA, VWA, and %VWA were significantly larger in the late stage than in the early stage (28.8 vs 21.6 mm(2), 15.8 vs 5.3 mm(2), 55.7% vs 24.9%, respectively) and lumen CSA was smaller in the late stage (12.8 vs 16.2 mm(2)). VWA correlated with vessel CSA, but not with lumen CSA. The time course of %VWA showed that %VWA in the late stage was a plateau state. From these findings, we concluded that the wall thickening process in SVGs begins within 6 months postoperatively and is accompanied by compensatory vessel enlargement.

Responses of interleukin-6 and tumor necrosis factor during and after cardiac surgery undergoing cardiopulmonary bypass and pancreatoduodenectomy.

To evaluate the effect of cardiopulmonary bypass on immunological function, we measured interleukin-6 (IL-6) and tumor necrosis factor (TNF) in 12 patients undergoing cardiac surgery during and after cardiopulmonary bypass, and in 10 patients with pancreatoduodenectomy. Plasma IL-6 levels were determined using the Human Interleukin 6 ELISA Kit, and TNF levels were determined using a highly sensitive sandwich enzyme immunoassay. In patients with cardiac surgery, plasma levels of IL-6 and TNF increased during cardiopulmonary bypass, and in patients with pancreatoduodenectomy, IL-6 and TNF levels significantly increased at the end of intraabdominal manipulation. These results suggest that endotoxin may have activated the immune system and stimulated cytokine production after pancreatoduodenectomy and during bypass.